Bayer stock gains as Roundup settlement hearing drives legal focus
Published on 09/14/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer AG stock (ISIN DE000BAY0017) is trading higher on September 14, 2026 as investors position ahead of a key US court hearing on the company’s proposed USD 7,250.0 million Roundup settlement, with Xetra quotes showing the shares around the mid-49-euro range in midday trading.
Roundup settlement hearing lifts sentiment
According to Goldesel on September 14, 2026, a court in Missouri is holding a hearing that day to consider final approval of Bayer’s planned Roundup settlement valued at USD 7,250.0 million, which aims to resolve tens of thousands of US lawsuits alleging that the weedkiller causes cancer.
In this coverage, the hearing in Missouri is described as a pivotal legal milestone for Bayer’s legacy Monsanto business, with the settlement designed to cover approximately 65,000 claims in US state and federal courts, which underscores the scale of the legal exposure the company is seeking to ring-fence.News Tribune
Price data from German stock portals show that Bayer shares on Xetra were up between about 2.5 percent and 3.9 percent on September 14, 2026, with intraday levels such as EUR 49.36 and EUR 49.79 reported around late morning, compared with prior closes slightly below EUR 48.50 as the market responded to the approaching hearing.MarketScreenerfinanzen.ch
Analyst consensus and year-to-date performance
A recent analyst overview compiled on September 13, 2026 indicates that the consensus stance on Bayer remains broadly constructive, with an average recommendation of Accumulate based on 18 analyses and an average price target of EUR 58.22, implying a double-digit upside from the high-40-euro trading range.MarketScreener
According to this analyst snapshot, Deutsche Bank Research reiterated a Buy recommendation on Bayer on September 10, 2026, with a price target of EUR 60.00, while Barclays maintained an Overweight rating and raised its target to EUR 70.00 on September 8, 2026, giving investors reference points that sit clearly above recent Xetra prices in the high-40-euro band.MarketScreener
As one German stock news article notes, Bayer shares have delivered a robust year-to-date gain in 2026, with one intraday snapshot on September 14, 2026 citing a performance of 33.96 percent since the start of the year when the stock was quoted at EUR 49.51, underscoring that the recent rally has not only been driven by the latest legal developments but also by broader re-rating trends.Goldesel
Recent operating and pipeline context
Beyond litigation, Bayer has also been highlighted for progress in its pharmaceutical and agricultural technology pipeline, with a recent weekly recap pointing to advances in oncology, cardiology and sustainability initiatives such as sevabertinib’s US Food and Drug Administration accelerated approval for HER2-mutant non-small cell lung cancer and a Phase II trial of the GIRK4 inhibitor BAY 3670549 in atrial fibrillation, alongside scale-up plans for iodine and NewGold canola for pharma and biofuels.TradingView
While the latest weekly note does not include new revenue or earnings figures, it illustrates how Bayer’s research and development portfolio continues to expand in high-value therapeutic areas, which is an important backdrop for investors evaluating the risk-reward balance as the company works through its Roundup legacy issues.
Event schedule and stock level
The economic and corporate calendar for September 14, 2026 lists the Bayer AG hearing on the approval of the glyphosate settlement before the Eighth Circuit Court in St. Louis, providing a clear time marker for the legal event that is currently shaping sentiment around the stock.finanzen.ch
As of the latest available Xetra data on September 14, 2026 around midday, Bayer stock was quoted close to EUR 49.77, with an intraday gain of about 3.3 percent from the previous close near EUR 48.18, and volumes above 700,000 shares traded, leaving the price still below the analyst consensus target of EUR 58.22 but significantly above levels seen earlier in the year.finanzen.chMarketScreener
Bayer stock key data
- Company: Bayer AG
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of September 14, 2026, 12:28): 49.77 EUR
- Market capitalization: [value] [currency] (as of [date])
- Sector / Industry: Health Care / Pharmaceuticals and Agriculture
- Index membership: DAX 40
